At a glance
- Originator GlaxoSmithKline
- Class
- Mechanism of Action Endothelin A receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Heart failure; Pulmonary hypertension
Most Recent Events
- 24 Jan 2001 SmithKline Beecham has merged with Glaxo Wellcome to form GlaxoSmithKline
- 24 Aug 1999 Preclinical development for Congestive heart failure in USA (Unknown route)
- 02 Oct 1998 Preclinical development for Pulmonary hypertension in USA (Unknown route)